Outcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis

February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024

Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel

June 2023 | Volume 22 | Issue 6 | Original Article | 588 | Copyright © June 2023

Evolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care

October 2022 | Volume 21 | Issue 10 | Original Article | 1054 | Copyright © October 2022

Background: Despite considerable advances in our understanding of the pathogenesis and treatment of psoriasis, data pertaining to racial/ethnic variations, effects on barrier function...
Read More

Therapies for Psoriasis: Clinical and Economic Comparisons

November 2020 | Volume 19 | Issue 11 | Original Article | 1101 | Copyright © November 2020

Background: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a ...
Read More

Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies Errata

June 2020 | Volume 19 | Issue 6 | Editorials | 573 | Copyright © June 2020

Erratum for article "Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies." Retriev...
Read More

Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata

June 2020 | Volume 19 | Issue 6 | Editorials | 571 | Copyright © June 2020

Erratum for article "Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)." Retrieved from Read More

Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis (Errata)

June 2020 | Volume 19 | Issue 6 | Editorials | 566 | Copyright © June 2020

Erratum for "Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis." Read More

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

April 2020 | Volume 19 | Issue 4 | Features | 436 | Copyright © April 2020

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?...
Read More

Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities

April 2020 | Volume 19 | Issue 4 | Original Article | 389 | Copyright © April 2020

Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/taz...
Read More

Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

October 2019 | Volume 18 | Issue 10 | Editorials | 1059 | Copyright © October 2019

Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).^1,2 The risk is especiall...
Read More

Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database

August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019

Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read More

Grover’s Disease Treated With Total Skin Electron Beam Radiotherapy

April 2019 | Volume 18 | Issue 4 | Case Reports | 392 | Copyright © April 2019

Persistent Grover's disease can cause significant symptoms of pruritus thereby decreasing quality of life. Many patients undergo successful conservative management of their disease; however, a subset...
Read More

Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review

April 2019 | Volume 18 | Issue 4 | Original Article | 387 | Copyright © April 2019

INTRODUCTION: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have b...
Read More

Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis

November 2018 | Volume 17 | Issue 11 | Original Article | 1211 | Copyright © November 2018

OBJECTIVE: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/t...
Read More

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years

August 2018 | Volume 17 | Issue 8 | Original Article | 826 | Copyright © August 2018

Background: Due to the chronic nature of psoriasis, it is important to assess the sustained response of treatments over time. Objective: To assess the efficacy of continuous treatment with guselkumab...
Read More

Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis

October 2017 | Volume 16 | Issue 10 | Original Article | 1002 | Copyright © October 2017

BACKGROUND: Psoriasis is associated with increased risk of major adverse cardiovascular events (MACE). OBJECTIVES: Compare MACE risk with biologics vs topical/phototherapy use. METHODS: Psoriasis Lo...
Read More

Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide

August 2017 | Volume 16 | Issue 8 | Original Article | 779 | Copyright © August 2017

Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treat...
Read More

Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis

August 2015 | Volume 14 | Issue 8 | Original Article | 805 | Copyright © August 2015

Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologics for psoriasis are directed at mor...
Read More

Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

July 2015 | Volume 14 | Issue 7 | Original Article | 706 | Copyright © July 2015

BACKGROUND: Safety surveillance is needed for biologic therapies for psoriasis.
OBJECTIVE: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis t...
Read More

New-Onset Vitiligo During Long-Term, Stable Infliximab Treatment of Pityriasis Rubra Pilaris

February 2013 | Volume 12 | Issue 2 | Case Reports | 217 | Copyright © February 2013

Incidents of new-onset vitiligo attributed to infliximab therapy for rheumatoid arthritis and ulcerative colitis have been reported. Reported cases share a common theme in that symptoms manifested in ...
Read More